吉非替尼治疗83例老年晚期非小细胞肺癌的疗效分析  

Efficacy analysis for 83 elderly patients with advanced non-small cell lung cancer treated with gefitinib

作　　者：刘雨桃[1,2] 郝学志[1,2] 李峻岭[1,2] 王彬[1,2] 胡兴胜[1,2] 王燕[1,2] 王子平[1,2] 王宏羽[1,2] 张湘茹[1,2] 石远凯[1,2] 

机构地区：[1]北京协和医学院 [2]中国医学科学院肿瘤医院内科,北京100021

出　　处：《中国新药杂志》2012年第9期1002-1006,共5页Chinese Journal of New Drugs

基　　金：卫生部医药卫生科技发展基金(200902002-1);中央保健专项基金(B2009B124);吴阶平医学基金会临床科研专项(320.6799.1109)

摘　　要：目的:探讨影响吉非替尼治疗晚期非小细胞肺癌(NSCLC)老年患者的疗效及其生存情况的临床因素。方法:对2007年1月-2009年6月在中国医学科学院肿瘤医院接受吉非替尼治疗的83例晚期NSCLC老年患者的临床资料进行回顾性分析。结果:全组患者中位年龄为70岁,客观有效率为32.5%,疾病控制率(DCR)为85.5%。吸烟状态对DCR方面的影响具有统计学意义(P=0.049)。中位无进展生存期(PFS)为11.6个月,不同性别、是否有吸烟史、病理类型是否为腺癌以及吉非替尼的疗效对PFS有显著影响(P<0.05)。中位总生存期(OS)为24.0个月,病理类型为腺癌(P<0.001)、吉非替尼治疗是否有效(P=0.029)以及吉非替尼治疗进展后可以继续接受其他抗肿瘤治疗(P=0.006)是明显改善总生存期的独立预后因素。结论:吉非替尼治疗老年晚期NSCLC有较好疗效。Objective：To explore the efficacy and survival of gefitinib for elderly patients with advanced NSCLC.Methods：The clinical data of 83 elderly advanced NSCLC patients referred to the Cancer Hospital Institute,Chinese Academy of Medical Sciences from Jan,2007 through Jun,2009 were analyzed retrospectively.Results：The median age of 83 elderly patients with advanced NSCLC was 70 years old.The objective response rate and oisease control rate were 32.5% and 85.5%.There was significantly statistical differences in disease control rate between two groups who had smoking history or not（P=0.049）.The median progression free survival was 11.6 months.Among the factors analyzed,sex,smoking history or not,pathological type and the clinical benefit rate had significant effects on the progression free survival（P0.05）.The median overall survival was 24.0 months.The independent prognostic factors to significantly improve the overall survival included adenocarcinoma（P0.001）,the clinical benefit rate（P=0.029） and receiving other anti-cancer treatment after gefitinib（P=0.006）.Conclusion：Gefitinib is a effective treatment for elderly patients with advanced NSCLC.

关 键 词：非小细胞肺癌 老年人 吉非替尼 疗效 

分 类 号：R969.4[医药卫生—药理学] R979.1[医药卫生—药学]